MA47494A - NEW USES OF ANTI-SIRPG ANTIBODIES - Google Patents

NEW USES OF ANTI-SIRPG ANTIBODIES

Info

Publication number
MA47494A
MA47494A MA047494A MA47494A MA47494A MA 47494 A MA47494 A MA 47494A MA 047494 A MA047494 A MA 047494A MA 47494 A MA47494 A MA 47494A MA 47494 A MA47494 A MA 47494A
Authority
MA
Morocco
Prior art keywords
new uses
sirpg antibodies
sirpg
antibodies
new
Prior art date
Application number
MA047494A
Other languages
French (fr)
Inventor
Vanessa Gauttier
Caroline Mary
Sabrina Pengam
Nicolas Poirier
Virginie Thepenier
Bernard Vanhove
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of MA47494A publication Critical patent/MA47494A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
MA047494A 2017-02-17 2018-02-15 NEW USES OF ANTI-SIRPG ANTIBODIES MA47494A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17305184 2017-02-17

Publications (1)

Publication Number Publication Date
MA47494A true MA47494A (en) 2019-12-25

Family

ID=58185462

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047494A MA47494A (en) 2017-02-17 2018-02-15 NEW USES OF ANTI-SIRPG ANTIBODIES

Country Status (11)

Country Link
US (2) US20190382483A1 (en)
EP (1) EP3583128A1 (en)
JP (2) JP7179743B2 (en)
KR (1) KR20190117670A (en)
CN (1) CN110300764A (en)
AU (1) AU2018221774A1 (en)
BR (1) BR112019016356A2 (en)
CA (1) CA3051318A1 (en)
IL (1) IL268731A (en)
MA (1) MA47494A (en)
WO (1) WO2018149938A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
MA56119A (en) 2019-06-07 2022-04-13 Alx Oncology Inc METHODS AND REAGENTS FOR REDUCING CD47-BINDING DRUG INTERFERENCE IN SEROLOGICAL ASSAYS
IL293199A (en) 2019-11-27 2022-07-01 Alx Oncology Inc Combination therapies for treating cancer
CN115768795A (en) * 2020-05-08 2023-03-07 依勒克拉疗法公司 SIRP alpha and SIRP beta 1 antibodies and uses thereof
EP4157315A1 (en) 2020-06-01 2023-04-05 ALX Oncology Inc. Combination therapies comprising a hypomethylation agent for treating cancer
WO2022120286A1 (en) 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
AU2022273727A1 (en) 2021-05-13 2023-11-09 ALX Oncology Inc. Combination therapies for treating cancer
WO2023086906A2 (en) * 2021-11-10 2023-05-19 Electra Therapeutics, Inc. Sirp gamma antibodies and uses thereof
US20240010701A1 (en) 2022-06-01 2024-01-11 ALX Oncology Inc. Combination therapies for treating urothelial carcinoma

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (en) 1997-09-26 2013-07-25 Pieris Proteolab Ag lipocalin muteins
GB0607943D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Biomarkers for chronic transplant dysfunction
ATE542830T1 (en) 2006-12-04 2012-02-15 Pasteur Institut OB-FOLD USED AS A SCAFFOLD FOR THE DEVELOPMENT OF NEW SPECIFIC BINDERS
KR20120107122A (en) * 2009-12-22 2012-09-28 노파르티스 아게 Tetravalent cd47-antibody constant region fusion protein for use in therapy
BR112016011195A2 (en) * 2013-11-18 2017-09-19 Rubius Therapeutics Inc ENUCLEATED ERYTHROID CELLS AND THEIR METHODS OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND THEIR USE, USE OF AN ERYTHROID CELL POPULATION, BIORACTOR, CELL MIXTURE AND MEDICAL DEVICE
CA2939293C (en) 2014-03-11 2023-10-03 The Board Of Trustees Of The Leland Standford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
US20180281938A1 (en) * 2015-01-22 2018-10-04 Sikorsky Aircraft Corporation Low noise rotor blade design
CA2983611A1 (en) * 2015-04-21 2016-10-27 Gilead Sciences, Inc. Treatment of chronic graft versus host disease with syk inhibitors
WO2016187226A1 (en) * 2015-05-18 2016-11-24 Ab Initio Biotherapeutics, Inc. Sirp polypeptide compositions and methods of use
JOP20190009A1 (en) * 2016-09-21 2019-01-27 Alx Oncology Inc Antibodies against signal-regulatory protein alpha and methods of use
EA201891882A1 (en) * 2017-02-17 2019-07-31 Осе Иммьюнотерапьютикс NEW ANTIBODIES TO SIRPa AND OPTIONS OF THEIR THERAPEUTIC APPLICATION

Also Published As

Publication number Publication date
CN110300764A (en) 2019-10-01
US20190382483A1 (en) 2019-12-19
US20220242951A1 (en) 2022-08-04
WO2018149938A1 (en) 2018-08-23
AU2018221774A1 (en) 2019-08-08
IL268731A (en) 2019-10-31
JP2020510643A (en) 2020-04-09
CA3051318A1 (en) 2018-08-23
JP7179743B2 (en) 2022-11-29
BR112019016356A2 (en) 2020-04-07
EP3583128A1 (en) 2019-12-25
JP2023010810A (en) 2023-01-20
KR20190117670A (en) 2019-10-16

Similar Documents

Publication Publication Date Title
MA47494A (en) NEW USES OF ANTI-SIRPG ANTIBODIES
MA49043A (en) STABLE ANTIBODY FORMULATION
MA47694A (en) ANTI-TIGIT ANTIBODY
MA46525A (en) ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS
MA49034A (en) ANTI-LAG3 ANTIBODY
MA50957A (en) ANTI-TIGIT ANTIBODIES AND THEIR METHODS OF USE
MA49683A (en) ANTI-CD8 ANTIBODIES AND THEIR USES
MA45123A (en) ANTI-TIM-3 ANTIBODIES AND THEIR METHODS OF USE
MA47789A (en) ANTI-PHF-TAU ANTIBODIES AND THEIR USES
MA53434A (en) ANTI-TIGIT ANTIBODIES
MA42925A (en) ANTI-TIGIT ANTIBODIES AND METHODS OF USE
MA42924A (en) OPTIMIZED VARIANTS OF ANTI-VEGF ANTIBODIES
MA42971A (en) ANTI-PDL1 ANTIBODIES, ACTIVABLE ANTI-PLD1 ANTIBODIES, AND METHODS OF USE THEREOF
MA47268A (en) ANTIBODY ANTI-GPC3
MA52884A (en) ANTI-IL-11 ANTIBODIES
MA50144A (en) ANTI-PEPTID BETA-AMYLOID ANTIBODIES N3PGLU AND ASSOCIATED USES
MA53356B1 (en) Subcutaneous anti-cd38 antibody formulations and uses thereof
MA49726A (en) FORMULATION OF ANTI-CGRP ANTIBODIES
MA51288A (en) INCRETIN ANALOGUES AND THEIR USES
MA51287A (en) INCRETIN ANALOGUES AND THEIR USES
MA45125A (en) ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND THEIR USES
MA49886A (en) ANTI-PAR2 ANTIBODIES AND THEIR USES
MA44665A (en) NEW ANTI-SIRPA ANTIBODIES AND THEIR THERAPEUTIC USES
MA52366A (en) OPTIMIZED ANTI-TL1A ANTIBODIES
MA52190A (en) ANTI-TREM-1 ANTIBODIES AND ASSOCIATED USES